Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
Tackling Complexities with Simplicity: PPI’s Ray Sheen on Threats, Opportunities, & the Uniqueness of Project Management
Boasting over 30 years of industry experience, Ray Sheen, President at Product & Process Innovation, Inc., (PPI), has felt ...